.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Find suppliers and generic API sources

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Baxter
Cipla
Moodys
Farmers Insurance
McKesson
Dow
Queensland Health
Chubb
Express Scripts

Generated: June 23, 2017

DrugPatentWatch Database Preview

Clindamycin phosphate - Generic Drug Details

« Back to Dashboard

What are the generic sources for clindamycin phosphate and what is the scope of clindamycin phosphate patent protection?

Clindamycin phosphate
is the generic ingredient in seventeen branded drugs marketed by Alvogen Inc, Watson Labs, Pharmacia And Upjohn, Mylan Pharms Inc, Wockhardt, Loch, West-ward Pharms Int, Bristol Myers Squibb, Sagent Pharms, Ingenus Pharms Llc, G And W Labs Inc, Marsam Pharms Llc, Akorn, Solopak, Abbvie, Igi Labs Inc, Paddock Llc, Vintage Pharms, Abraxis Pharm, Perrigo Co, Fougera Pharms, Teva Parenteral, Boca Pharma Llc, Teligent Pharma Inc, Fresenius Kabi Usa, Akorn Inc, Baxter Hlthcare, Perrigo New York, Fougera Pharms Inc, Bedford, Precision Dermat, Baxter Hlthcare Corp, Taro Pharm Inds, Perrigo Uk Finco, Sandoz Inc, Perrigo Pharma Intl, Medicis, Aqua Pharms Llc, and Actavis Mid Atlantic, and is included in sixty-six NDAs. There are seven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Clindamycin phosphate has one hundred and thirteen patent family members in thirty-six countries.

There are fifty-two drug master file entries for clindamycin phosphate. Thirty-three suppliers are listed for this compound.

Summary for Generic Name: clindamycin phosphate

Tradenames:17
Patents:7
Applicants:39
NDAs:66
Drug Master File Entries: see list52
Suppliers / Packagers: see list33
Bulk Api Vendors: see list54
Clinical Trials: see list889
Patent Applications: see list1,636
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:clindamycin phosphate at DailyMed

Pharmacology for Ingredient: clindamycin phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo New York
CLINDAMYCIN PHOSPHATE
clindamycin phosphate
SOLUTION;TOPICAL064050-001Nov 30, 1995ATRXNoNo► Subscribe► Subscribe
West-ward Pharms Int
CLINDAMYCIN PHOSPHATE
clindamycin phosphate
INJECTABLE;INJECTION062953-001Apr 21, 1988DISCNNoNo► Subscribe► Subscribe
Pharmacia And Upjohn
CLEOCIN T
clindamycin phosphate
SOLUTION;TOPICAL050537-001Approved Prior to Jan 1, 1982ATRXYesYes► Subscribe► Subscribe
Baxter Hlthcare
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
clindamycin phosphate
INJECTABLE;INJECTION050648-003Dec 29, 1989DISCNNoNo► Subscribe► Subscribe
West-ward Pharms Int
CLINDAMYCIN PHOSPHATE
clindamycin phosphate
INJECTABLE;INJECTION063068-001Aug 28, 1989DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: clindamycin phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Perrigo Pharma Intl
CLINDESSE
clindamycin phosphate
CREAM;VAGINAL050793-001Nov 30, 20045,266,329► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: clindamycin phosphate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,517,847 Topical gel delivery system► Subscribe
7,749,488Pharmaceutical foam► Subscribe
9,486,394Pharmaceutical foam► Subscribe
6,652,874 Pharmaceutical preparations and methods for their regional administration► Subscribe
6,416,778 Pharmaceutical preparations and methods for their regional administration► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: clindamycin phosphate

Country Document Number Estimated Expiration
Australia2004206769► Subscribe
Russian Federation2251410► Subscribe
Australia2002300175► Subscribe
Slovenia2052714► Subscribe
Cyprus1114646► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CLINDAMYCIN PHOSPHATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
00617Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
2013025,C1304992Lithuania► SubscribePRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
90049-3Sweden► SubscribePRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
13/044Ireland► SubscribePRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Colorcon
McKinsey
UBS
Boehringer Ingelheim
Dow
Covington
Argus Health
Harvard Business School
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot